AstraZeneca shares plunge as the firm's lung cancer study fails
London
ASTRAZENECA'S combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday.
The so-called Mystic study was the most anticipated clinical experiment in the pharmaceutical industry this year and the news saw the shares tumble more than 15 per cent in early trade, putting them on track for their worst day ever.
Initial results from Mystic found the combination of durvalumab and tremelimumab was no more effective at stopping disease progression than chemotherapy in patients expr…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Lululemon to shutter Washington distribution center, lay off 128 employees
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up